Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Techne Licenses Protein Synthesis Tech from MRC

NEW YORK (GenomeWeb) – Bio-Techne has licensed rights to a protein synthesis technology developed by the Medical Research Council Laboratory of Molecular Biology.

MRC Technology, the tech transfer organization for the UK's MRC, said that it has licensed to Bio-Techne the Genetically encoded Orthogonal Protection and Activated Ligation (GOPAL) technology, which enables the site-specific isopeptide bonds between proteins. The license enables the Minneapolis, Minn.-based life science research tools firm to develop reagent products using GOPAL.

According to MRC, the technology will first be applied to developing ubiquitin dimmers, with the potential for development of trimers and tetramers. It added that Bio-Techne's Boston Biochem company will investigate the use of GOPAL in "introducing post-translational modifications into proteins for structural and functional studies."

Financial and other terms of the license were not disclosed.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.